Phase I Trial of a Single Administration of aKLmRNA-Mediated Protein Replacement Therapy
Key claim: A Phase I trial at GARM Próspera is assessing the safety and exploratory biological aging impacts of a single intravenous infusion of alpha-Klotho mRNA therapy (AKL003) in 20 healthy participants.
Abstract
This is an open-label, single-arm, single-site Phase I trial in a total of 20 healthy participants at GARM Próspera, Roatán, Honduras. Each participant receives one intravenous administration of 0.5 mg AKL003 on Day 0.
Screening is followed by one treatment visit at GARM Próspera covering Day -1 to Day 2. Scheduled follow-up comprises Day 7 and the actual remote Final Visit (nominal Day 28 ±7 days), following local assessments under Investigator oversight.
Safety is assessed through adverse events, clinical examinations, vital signs, ECG and laboratory testing. Six months of passive safety follow-up after the individual Final Visit or Early Termination Visit.
PsyTool, QoL, Oura and DNA methylation assessments are retained. Exploratory changes do not establish clinical efficacy without a concurrent control group.
Why this matters
[anecdotal-biohack] The AKL003 trial adds a concrete experimental mRNA intervention to the longevity-clinic record, but its announcement is not evidence of widespread adoption or successful treatment. [mechanism-plausible] The aging-benefit hypothesis remains separate from the trial’s safety assessment and exploratory biomarker endpoints; the supplied finding reports no results establishing safety or health benefit.